Understood. The path we now are on has been set. As I mentioned they tried with another person, Tony, 2017. Surely a old Gilead exec could push a deal. That was the year of silence, I remember the entire year waiting to see if they had the combo trial enrolled, lots of presentation, no updates. Someone figured out on one presentation around June from the fractions they posted, how many they must have enrolled. When we finally got the update, the FDA asked for more people and more safety numbers.

At this point, I personally don't think bringing in someone else would change anything. The strategy has been set, and we are at the end game, not the first or second quarter, that a new person could change the game plan. Unless something drastic, like R/S, uplist, raise 100M, which honestly I think would be bad dilution for current shareholders. Great for the company future, bad for current shareholders. I've seen some very bad ways to raise money which totally wiped out old shareholders. They are trying to get everyone over the finish line, a inch at a time, grinding towards approval, that is usually not the case in other stocks I have seen....

2020 is science or bust.